Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

versus pemetrexed plus platin
nivolumab plus ipilimumab
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018
  NCT02477826
RCTmNSCLC - L1 - TMB>10Mbnivolumab plus ipilimumabplatinium chemotherapypatients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and TMB > 10mut/Mb139 / 160some concern
conclusif
  • demonstrated 42 % decrease in progression or deaths (PFS) (PE)